An FDA panel voted Tuesday in favor of recommending conditional approval of a new version of Cambridge biotech firm Genzyme’s (NASDAQ:[[ticker:GENZ]]) drug alglucosidase alfa (Myozyme) for Pompe disease, according to a report by Bloomberg News. Though the panel’s nod does not guarantee approval of the drug, it puts Genzyme one step closer to marketing a version of alglucosidase alfa made in larger batches than its approved version made in smaller containers.
Author: Ryan McBride
Ryan is an award-winning business journalist who contributes to our life sciences and technology coverage. He was previously a staff writer for Mass High Tech, a Boston business and technology newspaper, where he and his colleagues won a national business journalism award from the Society of American Business Editors and Writers in 2008. In recent years, he has made regular TV appearances on New England Cable News.
Prior to MHT, Ryan covered the life sciences, technology, and energy sectors for Providence Business News. He graduated with honors from the University of Rhode Island in 2001 with a bachelor’s degree in communications. When he’s not chasing down news, Ryan enjoys mountain biking and skiing in his home state of Vermont.
View all posts by Ryan McBride
